Merck KGaA
Merck KGaA Extends Collaboration with Quris-AI for Groundbreaking Advancements in Drug Safety
2023-10-02
Proxygen Eligible For €495 Million in Molecular Glue Degrader Collaboration with Merck KGaA
2022-06-06
FDA Approval of Tepotinib Sets Stage for Merck Versus Novartis Showdown in Metastatic NSCLC Space
2021-02-05
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115